

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joan M. ROBBINS and Mark J.
CANTWELL

Int'l Appln No.: PCT/US2005/011046

Int'l Filing Date: April 1, 2005

U.S. Appln No.: 10/594,850

For: USE OF 5,10-METHYLENE
TETRAHYDROFOLATE FOR THE
TREATMENT OF CANCER

Confirmation No.: 3709

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

June 20, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kenneth A. Weber
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KAW:sba
61072235 v1

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/594,850
				Filing Date	
				First Named Inventor	ROBBINS, Joan M.
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	022082-000610US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,534,519	07-09-1996	Spears et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AB	CARLSSON, G. et al.; "Phase II study of weekly 5-fluorouracil and 5,10-methylene-tetrahydrofolate in patients with advance gastrointestinal and breast cancer"; <u>The Cancer Journal</u> ; September-October, 1997; pp. 266-273; Vol. 10, No. 5.			<input type="checkbox"/>
	AC	GOLDBERG, Richard M. et al.; "A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer"; <u>Journal of Clinical Oncology</u> ; January 1, 2004; pp. 23-30; Vol. 22, No. 1; Grune and Stratton, New York, New York.			<input type="checkbox"/>
	AD	HURWITZ, H. et al.; "Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) a first-line therapy in subjects with metastatic CRC"; <u>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</u> ; May 2003; pp. 1-2.			<input type="checkbox"/>

Examiner Signature	/Marcos Sznajdman/	Date Considered	03/19/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.